Evaluation of clinical rationality of linezolid in our hospital in 2016

doi:10.12092/j.issn.1009-2501.2018.01.021

Abstract

Abstract:

AIM: To evaluate the clinical rationality, efficacy and safety of linezolid in our hospital in 2016 and to provide reference for its clinical application. METHODS: A retrospective study was conducted using the medical history data of patients treated with linezolid in 2016. The questionnaire was designed to compile statistics of rational use rate, to analyze the causes of irrational use, and to calculate the clinical cure rate, pathogen clearance rate and comprehensive cure rate, as well as to monitor the red blood cell, hemoglobin and platelet decline after treatment of linezolid. RESULTS: The rational use rate of linezolid was 48.1%, the irrational reasons are mainly that the indication was unreasonable and the course of treatment was unreasonable. The clinical cure rate was 40.4%, the pathogen clearance rate was 42.3%, and the comprehensive cure rate was 56.4%. The incidence of myelosuppression was 21.2% in patients whose average age was （81.4±8.7）years old, and the average course of treatment was （13.6±5.6）days. CONCLUSION: The rate of clinical rational use of linezolid needs to be improved in our hospital. The correct indication and course of treatment will improve the rational rate to a great extent. And the comprehensive curative effect is acceptable. But special attention should be paid to the occurrence of myelosuppression for the elderly patients.

Key words: linezolid, methicillin resistant Staphylococcus aureus (MRSA), thrombocytopenia

CLC Number:

R969.3

XU Jia, HUANG Qi, YANG Zhiling . Evaluation of clinical rationality of linezolid in our hospital in 2016[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 110-115.

References

［1］张莉, 孟现民, 张永信.利奈唑胺的药理学特点及临床应用［J］.上海医药, 2013, (13): 8-11.
［2］崔向丽, 赵志刚.新型噁唑烷酮类抗生素利奈唑胺［J］.中国新药杂志, 2008,17(6): 530-533.
［3］朱德妹, 张婴元, 周乐,等.利奈唑胺的体外抗菌作用研究［J］.中国感染与化疗杂志, 2008, 8(2): 81-88.
［4］梁蓓蓓,王睿.利奈唑胺、去甲万古霉素等抗菌药物对耐甲氧西林金黄色葡萄球菌的抗菌活性［J］.中国临床药理学与治疗学,2008,13(9):1044-1047.
［5］姚丹, 余方友, 黄晓颖,等.利奈唑胺耐药的粪肠球菌临床分离株的耐药性分析［J］.中国临床药理学杂志, 2015, 31(22): 2260-2262.
［6］方颍, 张嵘. 利奈唑胺耐药的MRSA中cfr基因的研究［C］//2015浙江省检验医学学术年会论文汇编.浙江：浙江省检验医学学术年会,2015:65-66.
［7］毛小红,方洁.利奈唑胺致血小板减少的危险因素分析［J］.中国临床药学杂志,2014,18(4):222-225.
［8］国家卫生计生委办公室, 国家中医药管理局办公室, 解放军总后勤部卫生部药品器械局.抗菌药物临床应用指导原则（2015年版）［M］.北京: 人民卫生出版社, 2015.
［9］Sanford JP.桑福德抗微生物治疗指南［M］. 北京: 中国协和医科大学出版社, 2014.
［10］黄勋, 邓子德, 倪语星,等.多重耐药菌医院感染预防与控制中国专家共识［J］.中国感染控制杂志, 2015,14(1): 1-9.
［11］中国严重脓毒症/脓毒性休克治疗指南(2014)［J］.中华内科杂志, 2015, 54(6): 401-406.
［12］郭代红, 王丽, 陈超,等.410例住院患者的利奈唑胺用药评估及影响因素分析［J］.中国药物应用与监测, 2011, 8(2): 69-74.
［13］抗菌药物临床试验技术指导原则写作组.抗菌药物临床试验技术指导原则［J］.中国临床药理学杂志, 2014,30(9): 844-856.
［14］吴建伟.老年人合理用药及用药安全的探讨［J］.临床合理用药杂志, 2015, 7(9): 31-32.
［15］姬琛华, 张竹青, 王晓媛,等.老年药物性肝损伤患者临床特征分析［J］.临床肝胆病杂志, 2017,33(3): 502-506.
［16］徐雅萍, 高媛, 李晓霞,等.高龄患者菌血症病原菌分布及与医院感染的关系探讨［J］.中华医院感染学杂志, 2010, 20(11): 1602-1604.
［17］刘勇, 吕燕平, 张艳莉.老年人医院获得性肺炎病原菌分布及耐药性探讨［J］.中国实用医药, 2015, 10(26): 164-166.
［18］Takada H, Hifumi T, Nishimoto N, et.al Linezolid versus vancomycin for nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus in the elderly: A retrospective cohort analysis: Effectiveness of linezolid in the elderly［J］.Am J Emerg Med, 2017, 35(2): 245-248.
［19］Abdelkader A, El-Mokhtar MA, Abdelkader O, et.al. Ultrahigh antibacterial efficacy of meropenem-loaded chitosan nanoparticles in a septic animal model［J］.Carbohydr Polym, 2017, 174: 1041-1050.
［20］付陈超, 文细毛, 任南,等.湖南省2013年重症监护病房血标本分离细菌耐药性监测［J］.中国抗生素杂志, 2015,40(7): 549-554.
［21］李娉, 李庆林, 刘丽萍,等.利奈唑胺和万古霉素对耐甲氧西林金黄色葡萄球菌感染疗效的Meta分析［J］.安徽医药, 2015, 19(5): 969-973.
［22］陈璋璋, 吕迁洲.利奈唑胺相关血小板减少的危险因素分析［J］.药物不良反应杂志, 2012,14(4): 218-223.
［23］Moraza L, Leache L, Aquerreta I, et al. Linezolid-induced haematological toxicity ［J］.Farm Hosp, 2015, 39(6): 320-326.

[1]	YUE Zhaorong, XIE Fei, WANG Xin, LI Hongyu. Effect of lienal polypeptide injection on primary immune thrombocytopenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1229-1236.
[2]	LIN Zhong, XIE Qunli, DAI Shuping, CHEN Jing, LIN Feiyang, ZHU Yanwu, YU Guoliang, ZHANG Yuanhuai, CUI Ke. Population pharmacokinetics of Linezolid in Chinese adult infection patients#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 992-999.
[3]	. Research progress of linezolid-induced lactic acidosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1408-1413.
[4]	ZHONG Ling, SHAO Hua, CHEN Yan, HU Linlin, YU Feng. Advance in linezolid-induced thrombocytopenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1196-1200.
[5]	LI Chun-xing, FU Qiang, ZHU Zhu. The tissue penetration and pharmacodynamics of linezolid in the infected tissues [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 349-355.
[6]	JIN Yan-jie, ZHANG Jing, LU Ke-peng, LIU Qian, LIN Li-min, SONG Hong-tao. Linezolid pharmacokinetics/pharmacodynamics and the development of dosage regimen design optimization [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1429-1434.
[7]	LIANG Bei-bei, WANG Rui, BAI Nan, CAI Yun. Mutant prevention concentrations study of linezolid and vancomycin against methicillin-resistant staphylococcus aureus isolates [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(3): 251-254.
[8]	LIANG Bei-bei, WANG Rui. Study on in vitro antimicrobial activity of linezolid, vancomycin and other antibacterials against 111 methicillin resistant staphylococcus aureus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(9): 1044-1047.
[9]	XIAO Xiu-mei, LIU Zheng-ying, ZHANG Xiao-wei, ZHANG Jie. Sensitivity analyses of linezolid against clinical gram-positive cocci isolates in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(9): 1048-1052.
[10]	YUAN Guo-long, XU Liang, LI Zhi, CHEN Lan-fang, XUAN Dan, LU Jin-ming. Effects of serum without immunoglobulin G from patients with systemic lupus erythematosus associated thrombocytopenia on megakaryocyto-poiesis of normal stem cells derived from cord blood [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(10): 1163-1167.
[11]	SU Ying-jie, LI Jing, YAO Ming-hui, GONG Qin-yan. Radioprotective effect of rhTPO on mice and MO7e cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(1): 66-71.
[12]	XU Guo-liang, XIAO Bing-hua, CHEN Qi, XU You-mei. Establishment of mouse model of Cytosine arabinoside-induced thrombocy-topenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(4): 387-390.